Berenberg Bank Analysts Give AstraZeneca (LON:AZN) a £124 Price Target

Berenberg Bank set a £124 ($151.13) price target on AstraZeneca (LON:AZN – Get Rating) in a report issued on Thursday, Borsen Zeitung reports.

AZN has been the topic of a number of other reports. Jefferies Financial Group set a £108 ($131.63) target price on shares of AstraZeneca in a research note on Thursday, February 9th. Credit Suisse Group set a £118 ($143.81) target price on shares of AstraZeneca in a research note on Friday, February 10th. UBS Group set a £119 ($145.03) target price on shares of AstraZeneca in a research note on Friday, March 10th. Shore Capital reiterated a buy rating on shares of AstraZeneca in a research note on Thursday, March 9th. Finally, Citigroup reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, November 16th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of £118.85 ($144.85).

AstraZeneca Stock Performance

Shares of LON:AZN opened at £108.14 ($131.80) on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.59 and a debt-to-equity ratio of 84.02. The company has a market capitalization of £167.62 billion, a price-to-earnings ratio of 6,179.43, a PEG ratio of 1.31 and a beta of 0.17. The firm’s 50-day moving average is £110.56 and its 200 day moving average is £107.71. AstraZeneca has a 12 month low of GBX 9,399 ($114.55) and a 12 month high of £128.28 ($156.35).

AstraZeneca Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 27th. Stockholders of record on Thursday, February 23rd will be paid a dividend of GBX 162.80 ($1.98) per share. The ex-dividend date of this dividend is Thursday, February 23rd. This is an increase from AstraZeneca’s previous dividend of $76.40. This represents a dividend yield of 1.51%. AstraZeneca’s dividend payout ratio (DPR) is currently 13,657.14%.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.